Epclusa

Gilead Sciences, Inc. (NASDAQ: GILD) announced fourth-quarter results Tuesday that revealed better-than-expected top- and bottom-line numbers — but the guidance was lackluster. The Analyst Bank of America Merrill Lynch analyst Ying Huang reiterated a Neutral rating on Gilead shares and...

Previewing first-quarter results of biotech companies, Jefferies said it sees some modest misses across the board, going by its deduction that the first quarter tends to be soft and its Rx analysis. However, the firm said this perspective would not dampen its enthusiasm, given a recent string of...

Gilead Sciences, Inc. (NASDAQ: GILD) revealed that the European Commission has accorded marketing authorization for its Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg), the first pan-genotypic, single tablet regimen for the treatment of adults, who are suffering from genotype 1-6 chronic hepatitis C...